Thyroid Gland Papillary Carcinoma

It is characterized by nuclear and cytoplasmic beta catenin expression indicating activation of Wnt/beta-catenin signaling pathway. We present a case of cribriform morular thyroid carcinoma with nodal recurrence, initially misdiagnosed as tall cell PTC highlighting its diagnostic challenges and clinical relevance of accurate diagnosis.

This study validated the hypothesis that Trp53 deletion and Braf mutation promote the progression of PTC to ATC through ultrasound monitoring and computer modeling. Certain PTCs with the potential for dedifferentiation exhibit a specific molecular expression profile, which may represent potential therapeutic targets.

RET fusion-positive PTC is associated with aggressive clinicopathological behavior and poor prognosis. This study highlights the importance of RET fusion testing in PTC for more accurate risk stratification and personalized therapeutic approaches, particularly for high-risk patients.

P2, N=29, Completed, Massachusetts Eye and Ear Infirmary | Active, not recruiting --> Completed

P=N/A, N=142, Not yet recruiting, University of Michigan Rogel Cancer Center | Trial completion date: Aug 2029 --> Aug 2027 | Trial primary completion date: Aug 2029 --> Aug 2027

Genetic polymorphisms in IL17A (rs2275913) and elevated plasma IL17A levels correlate with PTC susceptibility in the Chinese cohort. These findings suggest IL17A's potential as a biomarker for risk stratification and highlight inflammatory pathways in PTC pathogenesis.

These findings demonstrate that GAS8-AS1 may function as a tumor suppressor in DTCs, with its downregulation associated with disease progression and metastasis. The consistent loss of GAS8-AS1 expression and its functional impact on tumor progression suggest that it may serve as a valuable diagnostic and prognostic biomarker in DTCs.

Combined chemo-photothermal therapy significantly suppressed tumor growth in vivo with no obvious systemic toxicity, and the antitumor effect was associated with regulation of mitochondrial apoptosis-related genes. This multifunctional targeted nanoplatform exerts potent synergistic antitumor efficacy against aggressive PTC with good biosafety, providing a promising novel therapeutic strategy for radioiodine-refractory PTC.

Our findings uncover a previously unrecognized link between mitochondrial metabolic reprogramming, immune evasion and LNM in PTC and establish MGST1 as a robust biomarker for metastatic risk stratification and a pivotal metabolic-immune regulator. Moreover, the target-specific activity of toxoflavin provides a rational therapeutic strategy for patients with high-risk PTC characterized by MGST1-driven mitochondrial reprogramming and immune evasion.

miR-335-5p inhibited the expression of nearly all analyzed genes in less-differentiated thyroid cell lines. Thus, miR-335-5p may be a viable therapeutic target to restore radioiodine avidity in BRAF-mutant metastatic thyroid cancer and enhance KI treatment redifferentiation.

This study identifies a malignant cell-intrinsic signature for predicting PTC prognosis. Validated by single-cell data, our findings suggest that targeting ion channels may represent a potential therapeutic strategy for modulating neuro-immune interactions in thyroid cancer, pending experimental validation.